Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 25 for:    ventana

Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02802748
Recruitment Status : Completed
First Posted : June 16, 2016
Last Update Posted : September 20, 2018
Sponsor:
Collaborator:
Pierre Fabre Laboratories
Information provided by (Responsible Party):
SOLTI Breast Cancer Research Group

Brief Summary:
VENTANA is a "window-of-opportunity" trial that will explore whether, similar to CDK4/6 inhibitors, Oral Metronomic Vinorelbine in combination with Letrozole induces a superior anti-proliferative effect than Letrozole alone.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Oral Vinorelbine Drug: Letrozole Early Phase 1

Detailed Description:

VENTANA is a phase 0 multicenter, window of opportunity, three-arm, randomized clinical trial of oral metronomic vinorelbine (VNB) and letrozole versus either treatment alone in postmenopausal women with newly diagnosed untreated HR+ and HER2-negative, stage I-III operable breast cancer. Other eligibility criteria include primary tumor size 1 cm (cT1-3) and N0-1, ECOG PS 0-1 and evaluable diagnostic tumor sample.

Primary objective is to test if Oral Metronomic Vinorelbine and Letrozole induce a superior anti-proliferative effect than either drug alone in patients with early breast cancer defined as Luminal by PAM50/HER2-negative. This will be evaluated by measuring the expression of 11 proliferative genes contained in the PAM50/Prosigna® array (BIRC5, CCNB1, CDC20, CDCA1, CEP55, KNTC2, MKI67, PTTG1, RRM2, TYMS and UBE2C), as surrogate biomarker of its anticancer activity. By evaluating other breast cancer-related gene signatures (560 genes), the antiangiogenic and immunogenic potential of treatment arms will be compared and other genes regulated in a treatment-specific manner identified. These analyses will be performed in different PAM50-defined subtypes (Luminal, LuminalA or LuminalB). Clinical efficacy and safety of treatments will also be evaluated.

Patients will first undergo screening and mandatory collection of core tumor biopsies for study analysis. Patients are randomized (1:1:1) to receive Letrozole 2.5mg daily, oral Vinorelbine 50mg 3 days a week or Letrozole 2.5mg daily and oral Vinorelbine 50mg 3 times a week. After 3 weeks of treatment, patients will undergo surgery, and both pre-treatment and post-treatment surgery samples will be analyzed. Alternatively, if surgery will be delayed, a tumor core biopsy will be collected. Anyway, post-treatment sample should be collected within 5 days after end of treatment in order to observe the biological response.

Axillar and mammary surgery will be done according to local standards; however, sentinel lymph node biopsy previous to surgery is not permitted. Following surgical excision, adjuvant treatment will be as per investigator´s choice and local standards of care outside the scope of this protocol. End of study is 28 days (±3 days) after last study drug dose with a safety follow-up visit.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Randomized, Open-label, Three-arm, Parallel, Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole Versus Letrozole or Vinorelbine Alone in Post-menopausal Women With Hormone Receptor-positive HER2-negative Early Breast Cancer
Actual Study Start Date : July 2016
Actual Primary Completion Date : January 2018
Actual Study Completion Date : January 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Metronomic Vinorelbine + Letrozole
  • Oral Vinorelbine: 50 mg (30 mg + 20 mg) three times a week, for 3 weeks
  • Letrozole: 2.5mg daily, for 3 weeks
Drug: Oral Vinorelbine
Metronomic Schedule of Vinorelbine administered orally in a schedule monday-wednesday-friday, tuesday-thursday-saturday, etc
Other Name: Navelbine®

Drug: Letrozole
Letrozole will be administered orally at 2.5 mg QD for 3 weeks.

Active Comparator: Letrozole alone
Letrozole: 2.5mg daily, for 3 weeks
Drug: Letrozole
Letrozole will be administered orally at 2.5 mg QD for 3 weeks.

Active Comparator: Metronomic Vinorelbine alone
Oral Vinorelbine: 50 mg (30 mg + 20 mg) three times a week, for 3 weeks
Drug: Oral Vinorelbine
Metronomic Schedule of Vinorelbine administered orally in a schedule monday-wednesday-friday, tuesday-thursday-saturday, etc
Other Name: Navelbine®




Primary Outcome Measures :
  1. Changes in the expression of the PAM50 proliferation signature upon treatment in patients defined as Luminal by PAM50 [ Time Frame: At the time of surgery ]
    • Outcome measure determined by following formula: Mean suppression of proliferation signature score = 100 − [geometric mean (post treatment proliferation score/pre-treatment proliferation score · 100)].
    • Comparison of the Oral Metronomic Vinorelbine (VNB)+Letrozole arms versus VNB or Letrozole monotherapy arms in patients defined as Luminal by PAM50.


Secondary Outcome Measures :
  1. Changes in the expression of the PAM50 proliferation signature upon treatment in patients defined as Luminal by IHC and separately, in patients defined as either Luminal A or Luminal B by PAM50. [ Time Frame: At the time of surgery ]
    • Outcome measure determined by following formula: Mean suppression of proliferation signature score = 100 − [geometric mean (post treatment proliferation score/pre-treatment proliferation score · 100)].
    • Comparison of the 3 treatment arms in the entire study population (evaluable patients defined as Luminal by IHC) and separately, in patients defined as either Luminal A or Luminal B by PAM50

  2. Changes in % of Ki67-positive cells (per IHC) upon treatment [ Time Frame: At time of surgery ]
    Comparison of the 3 treatment arms in the entire PAM50-defined Luminal population (LuminalA+LuminalB) and separately, in the LuminalA or LuminalB subtypes.

  3. Changes in the expression of angiogenic gene signature upon treatment [ Time Frame: At the time of surgery ]
    Comparison of the 3 treatment arms in the entire PAM50-defined Luminal population (LuminalA+LuminalB) and separately, in the LuminalA or LuminalB subtypes.

  4. Changes in the expression of immune-response-related gene signature upon treatment [ Time Frame: At time of surgery ]
    Comparison of the 3 treatment arms in the entire PAM50-defined Luminal population (LuminalA+LuminalB) and separately, in the LuminalA or LuminalB subtypes.

  5. Changes in the expression of breast cancer related genes (contained in a 560 gene Custom CodeSet) upon treatment [ Time Frame: At the time of surgery ]
    • Expression data of breast cancer genes will be log base 2 transformed and normalized using 5 house-keeping genes
    • Analysis will be performed in the entire PAM50-defined Luminal population (LuminalA+LuminalB) and separately, in the LuminalA or LuminalB subtypes.
    • Aim of this outcome measure is to identify those genes with a significant difference between the VNB+Letrozole arms compared to the VNB or Letrozole monotherapy arms.

  6. Objective Response Rate (ORR) according to RECIST v1.1, assessed by ultrasound. [ Time Frame: Pre-surgery (3 weeks treatment) ]
  7. Safety profile [ Time Frame: Up to 7 weeks ]
    • Incidence and severity of Adverse Events (assessed by CTCAE v.4.03)
    • Incidence of treatment interruptions due to toxicity



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent for all study procedures in accordance with local regulatory requirements before protocol-specific procedures are started.
  • Postmenopausal status
  • Histologically confirmed invasive breast carcinoma, with all of the following characteristics: Primary tumor greater than or equal to (>/=) 1cm in largest diameter (cT1-3) and N0-Stage I to operable Stage III breast cancer
  • Scheduled or possibility of scheduling primary surgery within study window (surgery or biopsy within 5 days after treatment completion)
  • HR-positive breast cancer defined as ≥1% of anti-ER and/or anti-PgR stained tumor cells by IHC (per local assessment)
  • HER2-negative BC by IHC (score 0 or 1+) and/or FISH/CISH/SISH (defined as a ratio of HER2/CEP17<2 or single-probe average HER2 copy number <4 signals/cell), as per local assessment.
  • Known percentage of Ki67-positive tumor cells within pre-treatment sample or possibility of local assessment.
  • Available pre-treatment core or possibility to take a new biopsy with enough tumor sample for study analysis
  • ECOG performance status of 0 or 1
  • Adequate organ function, determined by laboratory tests performed within 7 days before treatment start

Exclusion Criteria:

  • Patients with cT4 or cN2-3 stage breast tumors
  • Bilateral invasive, multicentric or metastatic breast cancer
  • Patients with prior excisional biopsy of primary tumor and/or of axillar lymph nodes or or sentinel lymph node biopsy
  • Patients for whom upfront chemotherapy is clinically judged appropriate as optimal neoadjuvant treatment
  • Patients requiring imminent surgical procedure
  • Any prior treatment for breast cancer except for patients with Lobular Carcinoma In Situ (LCIS) treated with surgery or with Ductal Carcinoma In Situ (DCIS) treated exclusively with mastectomy. In both cases, surgery must have taken place >5 years prior diagnosis of current breast cancer
  • Other concurrent secondary malignancies, except for appropriately treated non-melanoma skin carcinoma, in situ melanoma and/or in situ cervical/colon cancer
  • Treatment with any investigational medicinal product or participation in another therapeutic clinical trial concurrently or in the 28 days prior randomization
  • Current uncontrolled severe systemic disease that could interfere with the intended therapy (e.g. clinical significant cardiovascular disease, pulmonary or metabolic disease, wound healing disorders, severe infection, heart failure, ischemic heart disease)
  • Hereditary fructose intolerance
  • Major surgical procedure or significant traumatic lesion within 28 days prior to treatment allocation or anticipated need for major surgery during the course of the study treatment, except if related with the breast cancer
  • Any psychological, family, sociological or geographical circumstance that could potentially represent an obstacle to compliance with the study protocol and the follow-up schedule; these circumstances will be discussed with the patient before enrolment in the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02802748


Locations
Layout table for location information
Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain, 08035
Hospital Clínic de Barcelona
Barcelona, Spain, 08036
Hospital de León
León, Spain, 24071
Hospital Universitario Ramón y Cajal
Madrid, Spain, 28034
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
Hospital Universitari Sant Joan de Reus
Reus, Spain, 43201
Clínica Quirón Sagrado Corazón
Sevilla, Spain, 41013
Fundación Instituto Valenciano de Oncología
Valencia, Spain, 46009
Hospital Clínico Universitario de Valencia
Valencia, Spain, 46010
Hospital Clínico Universitario Lozano Blesa
Zaragoza, Spain, 50009
Sponsors and Collaborators
SOLTI Breast Cancer Research Group
Pierre Fabre Laboratories
Investigators
Layout table for investigator information
Principal Investigator: Aleix Prat, MD, PhD Hospital Clínic de Barcelona

Additional Information:
Layout table for additonal information
Responsible Party: SOLTI Breast Cancer Research Group
ClinicalTrials.gov Identifier: NCT02802748     History of Changes
Other Study ID Numbers: SOLTI-1501
2015-004714-24 ( EudraCT Number )
First Posted: June 16, 2016    Key Record Dates
Last Update Posted: September 20, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by SOLTI Breast Cancer Research Group:
Early Breast Cancer
Hormone Receptor-positive
Window-of-opportunity
PAM50
Luminal A
Luminal B
proliferation signature
metronomic vinorelbine
letrozole

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Letrozole
Vinorelbine
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators